Comparison of the Old and New - Novel Mechanisms of Action for Anti-coronavirus Nucleoside Analogues

Authors

  • Joy E. Thames Dept. Chemistry and Biochemistry, University of Maryland, Baltimore County, 1000 Hilltop Circle Baltimore, MD 21250, USA
  • Katherine L. Seley-Radtke Dept. Chemistry and Biochemistry, University of Maryland, Baltimore County, 1000 Hilltop Circle Baltimore, MD 21250, USA

DOI:

https://doi.org/10.2533/chimia.2022.409

PMID:

38069712

Keywords:

nucleosides, nucleotides, RdRp, chain termination, lethal mutagenesis, translocation

Abstract

Over the past two and a half years the world has seen a desperate scramble to find a treatment for SARS-CoV-2 and COVID. In that regard, nucleosides have long served as the cornerstone to antiviral treatments due to their resemblance to the naturally occurring nucleosides that are involved in numerous biological processes. Unlike other viruses however, it was found early on during the search for drugs to treat SARS-1 and later MERS, that the coronaviruses possess a unique repair enzyme, an exonuclease (ExoN)[3] which rendered nucleoside analogues useless, thus negating their use.[4] During the current outbreak however, as both well-known and new nucleoside analogues were investigated or reinvestigated as a possible cure for SARS-CoV-2, several novel and/or lesser-known mechanisms of action were uncovered. This review briefly describes these mechanisms.

Funding data

Downloads

Published

2022-05-25

How to Cite

[1]
J. E. Thames, K. L. Seley-Radtke, Chimia 2022, 76, 409, DOI: 10.2533/chimia.2022.409.

Issue

Section

Scientific Articles